Literature DB >> 11903989

In vitro activities of ferrochloroquine against 55 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs.

B Pradines1, A Tall, C Rogier, A Spiegel, J Mosnier, L Marrama, T Fusai, P Millet, E Panconi, J F Trape, D Parzy.   

Abstract

The in vitro activities of ferrochloroquine, chloroquine, quinine, mefloquine, halofantrine, amodiaquine, artesunate, atovaquone, cycloguanil and pyrimethamine were evaluated against Plasmodium falciparum isolates from Senegal (Dielmo, Ndiop), using an isotopic micro-drug susceptibility test. The IC50 values for ferrochloroquine ranged from 0.55 to 28.2 nM and the geometric mean IC50 for the 55 isolates was 7.9 nM (95% CI, 6.5-9.7 nM). Ferrochloroquine was 35 times more active than chloroquine (35-fold greater against chloroquine-resistant isolates), quinine, mefloquine, amodiaquine, cycloguanil and pyrimethamine. Weak positive correlations were observed between the responses to ferrochloroquine and that to chloroquine, quinine, and amodiaquine, but not compulsorily predictive of cross-resistance. There was no significant correlation between the response to ferrochloroquine and that to mefloquine, halofantrine, artesunate, atovaquone, cycloguanil and pyrimethamine. Ferrochloroquine may be an important alternative drug for the treatment of chloroquine-resistant malaria.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11903989     DOI: 10.1046/j.1365-3156.2002.00848.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  21 in total

1.  Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax.

Authors:  Jutta Marfurt; Ferryanto Chalfein; Pak Prayoga; Frans Wabiser; Enny Kenangalem; Kim A Piera; Barbara Machunter; Emiliana Tjitra; Nicholas M Anstey; Ric N Price
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

2.  Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections.

Authors:  Christian Supan; Ghyslain Mombo-Ngoma; Matthias P Dal-Bianco; Carmen L Ospina Salazar; Saadou Issifou; Florent Mazuir; Aziz Filali-Ansary; Christophe Biot; Daniel Ter-Minassian; Michael Ramharter; Peter G Kremsner; Bertrand Lell
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

3.  In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum.

Authors:  Maud Henry; Sébastien Briolant; Albin Fontaine; Joel Mosnier; Eric Baret; Rémy Amalvict; Thierry Fusaï; Laurent Fraisse; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2008-05-27       Impact factor: 5.191

4.  Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal.

Authors:  Nathalie Wurtz; Bécaye Fall; Aurélie Pascual; Silmane Diawara; Kowry Sow; Eric Baret; Bakary Diatta; Khadidiatou B Fall; Pape S Mbaye; Fatou Fall; Yaya Diémé; Christophe Rogier; Raymond Bercion; Sébastien Briolant; Boubacar Wade; Bruno Pradines
Journal:  Malar J       Date:  2012-06-13       Impact factor: 2.979

Review 5.  The antimalarial ferroquine: from bench to clinic.

Authors:  C Biot; F Nosten; L Fraisse; D Ter-Minassian; J Khalife; D Dive
Journal:  Parasite       Date:  2011-08       Impact factor: 3.000

6.  Phase I randomized dose-ascending placebo-controlled trials of ferroquine--a candidate anti-malarial drug--in adults with asymptomatic Plasmodium falciparum infection.

Authors:  Ghyslain Mombo-Ngoma; Christian Supan; Matthias P Dal-Bianco; Michel A Missinou; Pierre-Blaise Matsiegui; Carmen L Ospina Salazar; Saadou Issifou; Daniel Ter-Minassian; Michael Ramharter; Maryvonne Kombila; Peter G Kremsner; Bertrand Lell
Journal:  Malar J       Date:  2011-03-01       Impact factor: 2.979

7.  Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs.

Authors:  Bécaye Fall; Silmane Diawara; Kowry Sow; Eric Baret; Bakary Diatta; Khadidiatou B Fall; Pape S Mbaye; Fatou Fall; Yaya Diémé; Christophe Rogier; Boubacar Wade; Raymond Bercion; Bruno Pradines
Journal:  Malar J       Date:  2011-10-20       Impact factor: 2.979

8.  Quinine-resistant malaria in traveler returning from Senegal, 2007.

Authors:  Bruno Pradines; Thierry Pistone; Khaled Ezzedine; Sebastien Briolant; Lionel Bertaux; Marie Catherine Receveur; Daniel Parzy; Pascal Millet; Christophe Rogier; Denis Malvy
Journal:  Emerg Infect Dis       Date:  2010-03       Impact factor: 6.883

9.  Concurrence of Plasmodium falciparum dhfr and crt mutations in northern Ghana.

Authors:  Frank P Mockenhaupt; J Teun Bousema; Teunis A Eggelte; Stephan Ehrhardt; Rowland N Otchwemah; Robert W Sauerwein; Ulrich Bienzle
Journal:  Malar J       Date:  2005-09-15       Impact factor: 2.979

10.  Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study.

Authors:  Bécaye Fall; Aurélie Pascual; Fatoumata D Sarr; Nathalie Wurtz; Vincent Richard; Eric Baret; Yaya Diémé; Sébastien Briolant; Raymond Bercion; Boubacar Wade; Adama Tall; Bruno Pradines
Journal:  Malar J       Date:  2013-03-20       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.